List of Excipients in Branded Drug IOPIDINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	IOPIDINE	apraclonidine hydrochloride	0065-0660	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	IOPIDINE	apraclonidine hydrochloride	0065-0660	HYDROCHLORIC ACID
Alcon Laboratories Inc	IOPIDINE	apraclonidine hydrochloride	0065-0660	SODIUM ACETATE

IOPIDINE Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

IOPIDINE is apraclonidine hydrochloride ophthalmic solution, marketed in 0.5% and 1% strengths for short-term reduction of elevated intraocular pressure. Its formulation is simple and mature: apraclonidine hydrochloride in an aqueous buffered system containing sodium chloride, sodium acetate, benzalkonium chloride, purified water, and pH adjusters. The commercial opportunity is therefore unlikely to depend on a new chemical entity patent. It lies in preservative-free delivery, improved tolerability, differentiated packaging, hospital-use formats, and reliable supply of generic ophthalmic products.

What is IOPIDINE and how is it used?

IOPIDINE contains apraclonidine, an alpha-adrenergic agonist that reduces aqueous humor production and increases uveoscleral outflow. The product is used primarily as an adjunct for short-term IOP reduction, including before and after laser procedures. Chronic use is limited by tachyphylaxis and a high rate of ocular allergic reactions.

Attribute	IOPIDINE 0.5%	IOPIDINE 1%
Active ingredient	Apraclonidine hydrochloride	Apraclonidine hydrochloride
Concentration	5 mg/mL	10 mg/mL
Dosage form	Sterile ophthalmic solution	Sterile ophthalmic solution
Route	Topical ophthalmic	Topical ophthalmic
Main use	Short-term IOP reduction	Short-term IOP reduction
Preservative	Benzalkonium chloride, generally 0.01%	Benzalkonium chloride, generally 0.01%
Typical clinical role	Lower-strength adjunct	Higher-strength IOP reduction
Chronic-use limitation	Tachyphylaxis and allergy	Tachyphylaxis and allergy

The FDA labeling identifies IOPIDINE as a short-term treatment rather than a preferred chronic glaucoma therapy because the drug’s effect can diminish with continued administration and ocular hypersensitivity can develop (U.S. Food and Drug Administration [FDA], 2017).

What excipients are used in IOPIDINE?

The labeled IOPIDINE formulation uses a conventional aqueous ophthalmic excipient platform:

Excipient	Formulation role	Commercial relevance
Benzalkonium chloride	Antimicrobial preservative	Effective and inexpensive, but associated with ocular-surface toxicity and intolerance
Sodium chloride	Tonicity adjustment	Supports ocular comfort and isotonicity
Sodium acetate	Buffer component	Controls pH and supports chemical stability
Hydrochloric acid and sodium hydroxide	pH adjustment	Establishes the target formulation pH
Purified water	Vehicle	Sterile aqueous delivery medium

The product is formulated at an acidic to near-neutral pH range appropriate for apraclonidine stability and ophthalmic administration. Exact target specifications, preservative concentration, osmolality limits, and release criteria should be taken from the current approved labeling and the applicable regulatory file rather than inferred from a commercial package insert.

Why benzalkonium chloride is the main excipient opportunity

Benzalkonium chloride, commonly abbreviated BAK, is the most commercially important excipient issue in IOPIDINE. BAK provides broad antimicrobial protection in multidose containers, but repeated exposure can damage the ocular surface, increase staining, and worsen symptoms in patients with ocular-surface disease.

The opportunity is strongest in:

• Preservative-free unit-dose vials
• Low-BAK multidose systems
• Alternative preservatives with ophthalmic compatibility
• Metered-dose pumps that limit microbial ingress
• Container systems that reduce repeated exposure
• Hospital and laser-center packs designed for single-procedure use

A preservative-free product would not automatically be clinically superior for every patient. It would, however, create a differentiated product for patients receiving repeated topical therapy, patients with dry eye, and patients undergoing multiple ophthalmic procedures.

What formulation patents protect IOPIDINE?

IOPIDINE is an old ophthalmic product, and the principal commercial protection is not expected to come from an unexpired composition-of-matter patent. Apraclonidine entered clinical and commercial use decades ago, and generic apraclonidine ophthalmic solutions have been approved in the United States.

The original product formulation is also unlikely to provide a strong blocking position by itself. A generic applicant can generally pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence, bioequivalence where required, quality, sterility, container-closure integrity, and adequate stability.

Potential new patent categories include:

Patent category	Potential claim scope	Relative value
Preservative-free formulation	Apraclonidine solution without BAK, with defined pH and stability	Medium
Alternative preservative	Specific preservative system and concentration range	Medium
Multidose delivery	Preservative-free pump or valve system	Medium to high
Unit-dose packaging	Container material, fill volume, oxygen barrier, or light protection	Low to medium
Stability formulation	Buffer, pH, tonicity, and antioxidant combination	Medium
Combination therapy	Apraclonidine with another IOP-lowering agent	Medium, but method-of-use dependent
Method of use	Perioperative IOP control or selected patient populations	Medium
Manufacturing process	Sterilization, filtration, filling, or impurity-control process	Low to medium unless technically difficult

A patent covering only the presence of a routine ophthalmic excipient is vulnerable to written-description, enablement, obviousness, and infringement challenges. A stronger patent would combine a specific composition with measurable technical effects, such as improved stability, reduced preservative exposure, reduced ocular-surface toxicity, or reliable multidose sterility.

When does IOPIDINE lose exclusivity?

IOPIDINE’s original regulatory and patent exclusivity periods have expired. The FDA Orange Book identifies approved drug products and any relevant listed patents or regulatory exclusivities; it should be reviewed for the current NDA and approved generic products before a filing or transaction (FDA, 2024).

Exclusivity element	IOPIDINE position
New chemical entity exclusivity	Expired
Original product patent protection	Expired or commercially non-blocking
Pediatric exclusivity	No current blocking relevance identified
Orphan-drug exclusivity	Not applicable to the core product
Orange Book strategy	Generic applicants can generally pursue ANDA pathways
Main remaining barriers	Sterile manufacturing, formulation robustness, container closure, supply reliability, and clinical tolerability

The absence of meaningful original exclusivity does not eliminate commercial barriers. Ophthalmic products remain difficult to manufacture because they require validated aseptic processing, low particulate levels, sterility assurance, extractables and leachables control, and container-closure integrity.

What is the FDA regulatory status of IOPIDINE and generic apraclonidine?

IOPIDINE was approved as a prescription ophthalmic product under NDA 019658. Generic apraclonidine ophthalmic solutions have been approved in the United States in 0.5% and 1% strengths.

A conventional generic program would normally rely on:

1. Pharmaceutical equivalence to the reference listed drug.
2. The same active ingredient, strength, dosage form, and route.
3. Comparative quality and stability data.
4. Sterility and preservative-effectiveness testing.
5. An ANDA with the applicable certification under 21 U.S.C. § 355(j).

A product with a materially different formulation, such as a preservative-free multidose system, may require a regulatory strategy beyond a standard ANDA if the formulation or device changes cannot be bridged to the reference product. Depending on the proposed claims and differences, a 505(b)(2) application may be relevant.

FDA approval risks for an excipient-differentiated product

The major regulatory risks are:

• Failure to demonstrate equivalent drug delivery from a new container system
• Inadequate antimicrobial preservation
• Incompatibility between apraclonidine and the container closure
• Increased degradation under light or elevated temperature
• Ocular irritation from a replacement preservative
• Dose nonuniformity in low-volume or multidose devices
• Failure of sterility or particulate specifications
• Device-drug combination review delays

The excipient strategy should be designed with the final container, fill volume, closure system, sterilization method, and administration profile from the beginning. Changing the container late in development can trigger new extractables, leachables, stability, and human-factors work.

What commercial opportunities exist for IOPIDINE excipients?

Preservative-free unit-dose IOPIDINE

This is the clearest formulation opportunity. A 0.5% or 1% preservative-free product could target laser centers, ambulatory surgery centers, ophthalmology practices, and patients with ocular-surface disease.

The primary advantages are:

• Reduced BAK exposure
• Single-procedure packaging
• Lower cross-contamination risk
• Simplified administration in procedural settings
• Potential positioning for patients intolerant of preserved drops

The disadvantages are higher packaging cost, greater waste, more complex logistics, and possible pressure on reimbursement.

Low-BAK or alternative-preservative products

A low-BAK formulation could preserve the convenience of a multidose bottle while reducing cumulative preservative exposure. The product would need comparative ocular tolerability data or a persuasive clinical rationale. A new preservative can create its own toxicity and compatibility issues, so a simple substitution is not automatically commercially attractive.

Preservative-free multidose systems

A preservative-free multidose pump could command a higher price than a standard bottle. The business case depends on whether the device can maintain sterility after repeated use without excessive priming volume or dosing variability.

The strongest intellectual-property position would combine:

• The apraclonidine formulation
• A specific pump or valve architecture
• Microbial ingress control
• Dose uniformity
• Defined in-use stability
• Compatibility with acidic aqueous solutions

Improved comfort and ocular-surface tolerability

The IOPIDINE label identifies ocular discomfort, allergic reactions, and eyelid or conjunctival effects as relevant limitations. An optimized formulation could use pH, osmolality, viscosity, and preservative reduction to improve comfort. Excessive viscosity could blur vision or alter dosing, so a formulation claim should be supported by measurable performance and clinical tolerability data.

Hospital and procedural-use packaging

IOP control around laser treatment creates a concentrated commercial setting. A supplier could develop:

• Single-use vials
• Procedure-specific kits
• Two-dose packs for pre- and post-procedure use
• Pharmacy bulk packages where permitted
• Barcoded packs for ambulatory surgery centers
• Short-dated or ready-to-use formats for hospital pharmacies

These opportunities may produce better margins than a commodity retail generic because packaging, supply assurance, and workflow integration become part of the value proposition.

Which companies are challenging or competing with IOPIDINE?

Competition comes from both apraclonidine generics and alternative IOP-lowering drugs. The main therapeutic alternatives include brimonidine, timolol, dorzolamide, brinzolamide, prostaglandin analogs, and fixed-dose combinations.

Competitor category	Examples	Competitive effect
Apraclonidine generics	0.5% and 1% ophthalmic solutions	Direct price competition
Alpha-2 agonists	Brimonidine ophthalmic products	May replace apraclonidine where longer-term use is required
Beta blockers	Timolol	Established low-cost alternative
Carbonic anhydrase inhibitors	Dorzolamide, brinzolamide	Used alone or in combination
Prostaglandin analogs	Latanoprost and related products	Preferred for many chronic glaucoma patients
Fixed combinations	Multiple active-ingredient combinations	Reduce dosing burden and substitution risk

Apraclonidine remains more relevant for acute or short-term IOP reduction than for chronic maintenance therapy. That narrows the addressable market but can support procedural and institutional positioning.

Are there Paragraph IV challenges or IOPIDINE patent lawsuits?

Generic entry into an old ophthalmic product is more likely to proceed through ordinary ANDA pathways than through a commercially significant Paragraph IV dispute. No major, currently active IOPIDINE patent litigation or settlement agreement is identified in the core product record reviewed for this analysis.

A Paragraph IV certification would matter only if an applicant challenged an unexpired Orange Book-listed patent. For IOPIDINE, the principal commercial risk is not litigation delay. It is price erosion from multiple generic suppliers and substitution by other IOP-lowering medicines.

A transaction involving IOPIDINE should still review:

• The current Orange Book patent listing
• FDA approval letters for the reference and generic products
• ANDA litigation records
• Abbreviated New Drug Application settlement disclosures
• Any device patents covering a differentiated container
• State-level substitution and reimbursement conditions

How strong is the IOPIDINE patent estate?

The legacy patent estate is weak as a barrier to ordinary generic entry. A new excipient or delivery patent could be stronger if it protects a clinically meaningful improvement that is difficult to design around.

Estate component	Strength assessment
Active ingredient	Weak; old molecule with expired exclusivity
Standard aqueous solution	Weak; routine formulation technology
BAK-preserved bottle	Weak; conventional ophthalmic platform
Preservative-free unit dose	Moderate if supported by stability and use claims
Preservative-free multidose device	Moderate to strong if device and formulation claims are integrated
Method of use	Moderate, but limited by narrow clinical use and prior art
Manufacturing process	Variable; strongest where impurity control or sterility process is difficult to replicate

The most defensible strategy would use layered claims covering composition, packaging, in-use stability, device operation, and defined clinical use. A single broad formulation claim would be easier for competitors to challenge or design around.

What generic launch scenarios exist?

Low-price conventional generic

A standard BAK-preserved bottle would have the lowest development cost and fastest route to market. It would also face the highest price pressure.

Premium preservative-free product

A preservative-free unit-dose product could command a premium, especially in procedural and ocular-surface-sensitive markets. Commercial success would depend on reimbursement and physician recognition of the tolerability benefit.

Device-led product

A preservative-free multidose system could create the strongest differentiation. It would require greater development capital, device validation, human-factors work, and supply-chain control.

Licensed formulation platform

A company with a proven ophthalmic preservative-free platform could license the formulation and container technology to a generic or specialty-pharmaceutical manufacturer. The license value would depend on freedom to operate, demonstrated stability, and regulatory precedent for the platform.

What manufacturing and IP barriers affect IOPIDINE?

The active pharmaceutical ingredient is not the main barrier. The more important barriers are:

• Sterile aqueous filling
• Apraclonidine impurity control
• pH and buffer reproducibility
• Low particulate performance
• Container-closure integrity
• Preservative effectiveness
• Device extractables and leachables
• In-use stability after opening
• Reliable availability of ophthalmic-grade packaging

Manufacturers with existing sterile ophthalmic capacity have a structural advantage. Contract development and manufacturing organizations with preservative-free filling and ophthalmic device experience are potential partners for a differentiated product.

How does IOPIDINE compare with brimonidine?

Brimonidine is generally better positioned for longer-term glaucoma management, while apraclonidine is more often used for short-term IOP reduction. Both are alpha-adrenergic therapies, but they have different tolerability, use patterns, and commercial positioning.

Factor	Apraclonidine	Brimonidine
Primary role	Short-term IOP reduction	Chronic and adjunctive IOP control
Tachyphylaxis concern	Significant	Also relevant, but product use is broader
Allergy concern	High	Clinically important
Generic competition	Mature	Mature
Formulation opportunity	Preservative-free and procedural formats	Preservative-free chronic-use formats
Commercial niche	Laser and acute procedural settings	Broad glaucoma market

A company pursuing IOPIDINE should avoid competing solely on chronic glaucoma volume. The better position is a focused product for short-duration, procedure-linked use with improved tolerability or workflow efficiency.

Key Takeaways

• IOPIDINE is an old apraclonidine ophthalmic product with expired original exclusivity and generic competition.
• The core BAK-preserved aqueous formulation offers limited patent or commercial differentiation.
• The strongest opportunity is a preservative-free unit-dose or multidose delivery system.
• Excipient claims should be integrated with packaging, stability, sterility, and in-use performance.
• The principal regulatory route for a conventional product is an ANDA; materially different formulations may require a 505(b)(2) strategy.
• Active Paragraph IV litigation and settlement risk appear limited compared with price erosion and therapeutic substitution.
• Procedural ophthalmology, laser centers, ambulatory surgery centers, and ocular-surface-sensitive patients are the most credible target segments.
• Manufacturing capability, container technology, and supply reliability are more important barriers than active-ingredient access.

FAQs

Is IOPIDINE still protected by a composition-of-matter patent?

No current composition-of-matter protection is expected to block generic apraclonidine ophthalmic products. Commercial review should focus on current Orange Book listings and any device or formulation patents associated with a new product.

Can a preservative-free IOPIDINE product receive ANDA approval?

Possibly, but the regulatory pathway depends on the degree of formulation and container difference. A materially different preservative-free or multidose delivery system may require a 505(b)(2) strategy rather than a simple ANDA.

Which excipient is most important in an IOPIDINE reformulation?

Benzalkonium chloride is the most important target because it is the principal preservative and the main source of ocular-surface differentiation. Buffer, pH, tonicity, viscosity, and container compatibility remain critical development variables.

Is apraclonidine suitable for chronic glaucoma treatment?

Its use is generally limited by tachyphylaxis and ocular allergy. The commercial opportunity is stronger in short-term or procedural IOP control than in chronic maintenance therapy.

What is the best licensing opportunity around IOPIDINE?

The strongest licensing opportunity is a validated preservative-free ophthalmic platform that combines apraclonidine formulation claims with a multidose container or procedure-specific unit-dose packaging system.

References

1. DailyMed. (n.d.). Iopidine-0.5% apraclonidine hydrochloride ophthalmic solution; Iopidine-1% apraclonidine hydrochloride ophthalmic solution. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2017). Iopidine ophthalmic solution prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug product information and Drugs@FDA. FDA.

5. United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (1999). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice. FDA.